IMRX
Immuneering Corp
$5.11
-0.25 (-4.66%)
At close · Jul 10
Market Cap
$330.60M
Shares
64,697,402
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2023
Net Income
-$56.02M
+8.2%
FY2025
Gross Margin
50.11%
+5.6pp
FY2022
Operating Margin
-16325.77%
-14696.6pp
FY2022
Diluted EPS
-$1.27
+37.7%
FY2025
Operating Cash Flow
-$45.34M
+17.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | — | — | $0 | $316.95K | $2.08M | |
| — | — | — | $0 | $158.12K | $1.15M | |
| — | — | — | $0 | $158.83K | $926.89K | |
| — | — | — | — | 50.11% | 44.56% | |
| $41.22M | $42.05M | $47.96M | $41.62M | $36.27M | $26.54M | |
| $17.98M | $17.3M | $16.08M | $16.76M | $15.61M | $8.27M | |
| $29.27K | $29.27K | $29.27K | $29.27K | $30.05K | — | |
| $320.66K | $324.52K | $355.81K | — | — | — | |
| $59.23M | $59.38M | $64.07M | $58.41M | $51.9M | $34.81M | |
| -$59.23M | -$59.38M | -$64.07M | -$58.41M | -$51.74M | -$33.89M | |
| — | — | — | — | -16325.77% | -1629.17% | |
| -$58.91M | -$59.05M | -$63.72M | — | — | — | |
| $3.96M | $3.04M | $2.59M | $3.61M | $1.01M | $169.9K | |
| $825.4K | $311.67K | $441.49K | $1.33M | $216.84K | -$127.06K | |
| — | — | — | — | -$50.51M | -$33.84M | |
| — | $0 | — | — | -$307.49K | -$307.49K | |
| -$54.44M | -$56.02M | -$61.04M | -$53.47M | -$50.51M | -$33.54M | |
| — | — | — | — | -15937.29% | -1612.33% | |
| -$54.68M | -$55.94M | -$61.04M | -$53.44M | -$50.49M | -$33.58M | |
| USD/shares | — | -$1.27 | -$2.04 | -$1.88 | -$1.91 | -$2.46 |
| USD/shares | — | -$1.27 | -$2.04 | -$1.88 | -$1.90 | -$2.46 |
| shares | — | 44.01M | 29.98M | 28.42M | 26.39M | 13.61M |
| shares | — | 44.01M | 29.98M | 28.42M | 26.39M | 13.61M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.52×